Shareholding disclosure

Idorsia Ltd

Declared position

22.13%

Threshold

Crossed upwards

Timeline

Published

13.01.2023

Transaction

09.01.2023

Transfer date

10.01.2023

Voting rights breakdown

Voting rights acquired22.13%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAN1B00037

Beneficial owner

Idorsia Ltd

Declared address

Idorsia Ltd, 4123 Allschwil

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Idorsia Ltd

Santhera Pharmaceuticals Holding AG13.01.2023TAN1B00037

Disclosure summary

Idorsia Ltd disclosed a holding in Santhera Pharmaceuticals Holding AG on the acquisition side, published by SIX Exchange Regulation on 13.01.2023, at 22.13% of voting rights. Notice category: Single shareholder.

Disclosed position

22.13%

Voting rights acquired

Voting rights acquired22.13%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Idorsia Ltd disclosed a holding in Santhera Pharmaceuticals Holding AG, published on 13.01.2023.

Publication date13.01.2023

Transaction date09.01.2023

Transfer date10.01.2023

Issuing companySanthera Pharmaceuticals Holding AG

Beneficial ownerIdorsia Ltd

Declared addressIdorsia Ltd, 4123 Allschwil

CategorySingle shareholder

Voting rights acquired22.13%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAN1B00037

Commercial register

CHE-340.129.854

Registered

Zefix record

Source: SIX Exchange Regulation · Publication date: 13.01.2023

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open